Active Osteonectin (ON) Homo sapiens (Human) Active protein

SPARC; BM-40; Secreted Protein,Acidic,Cysteine-Rich; Basement-membrane protein 40; Secreted protein acidic and rich in cysteine

Add to Cart Distributors
Overview
Properties
  • Buffer FormulationPBS, pH7.4, containing 5% Trehalose.
  • Traits Freeze-dried powder, Purity > 95%
  • Isoelectric Point4.4
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Active Osteonectin (ON) Packages (Simulation)
  • Active Osteonectin (ON) Packages (Simulation)
  • APA791Hu61.jpg Figure. SDS-PAGE
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Activity test

SPARC, also known as osteonectin(ON), is the founding member of a family of secreted matricellular proteins with similar domain structure. The 302 amino acid (aa), 43 kDa protein contains a 17 aa signal sequence, an N-terminal acidic region that binds calcium, a follistatin domain containing Kazal-like sequences, and a C-terminal extracellular calcium (EC) binding domain with two EF-hand motifs. SPARC is produced by fibroblasts, capillary endothelial cells, platelets and macrophages, especially in areas of tissue morphogenesis and remodeling. SPARC shows context-specific effects, but generally inhibits adhesion, spreading and proliferation, and promotes collagen matrix formation. Besides, Collagen Type I Alpha 2 (COL1a2)) has been identified as an interactor of SPARC, thus a functional binding ELISA assay was conducted to detect the interaction of recombinant human SPARC and recombinant human COL1a2. Briefly, SPARC was diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100 μl were then transferred to COL1a2-coated microtiter wells and incubated for 1h at 37℃. Wells were washed with PBST and incubated for 1h with anti-SPARC pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody for 1h at 37℃, wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50 µL stop solution to the wells and read at 450/630 nm immediately. The binding activity of recombinant human SPARC and recombinant human COL1a2 was shown in Figure 1, and this effect was in a dose dependent manner.

Usage

Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

Storage

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

Stability

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Citations

  • Growth hormone replacement therapy regulates microRNA-29a and targets involved in insulin resistancePubMed: 26199111
  • Effect of resistance ladder training on SPARC expression in skeletal muscle of hindlimb immobilized ratsPubMed: 26467437
  • An Attempt to Evaluate Selected Aspects of “Bone–Fat Axis” Function in Healthy Individuals and Patients With Pancreatic CancerPubMed: 26266370
  • A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesotheliomaPubmed:26889976
  • Associations between FGF21, osteonectin and bone turnover markers in type 2 diabetic patients with albuminuria.pubmed:27916484
  • Association of Bone Metabolic Markers With Diabetic Retinopathy and Diabetic Macular Edema in Elderly Chinese Individuals With Type 2 Diabetes Mellituspubmed:29078839
  • Testican 1 (SPOCK1) and protein tyrosine phosphatase, receptor type S (PTPRS) show significant increase in saliva of tobacco users with oral cancerDoi: 10.1177/2057178X18800534
  • Osteoconductive potential of PLGA/bioglass composite biomaterials

Recommend products